Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication

American Journal of Medicine

Volumn 107, Issue 3, 1999, Pages 234-239

  Antonicelli, Roberto ^a   Sardina, Marco ^a   Scotti, Aurelio ^b   Bonizzoni, Erminio ^c   Paciaroni, Enrico ^a  

^a INRCA   (Italy)

^b Italfarmaco SpA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HEPARIN CALCIUM; PLACEBO;

ADULT; AGED; ARTERY DISEASE; ARTICLE; BLEEDING; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; EPISTAXIS; FEMALE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERFORMANCE; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; WALKING;

EID: 0032876370     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00224-7     Document Type: Article

References (26)

1. Kannel W.B., Skinner J.J., Schwartz M.J., Shurtleff D. Intermittent claudication incidence in the Framingham study . Circulation. 41:1970;875-883.
2. Hughson W.G., Mann J.I., Garrod A. Intermittent claudication prevalence and risk factors . BMJ. 1:1978;1379-1381.
3. Reid D.D., Brett G.J., Hamilton P.J.S., et al. Cardiorespiratory disease and diabetes among middle aged male civil servants. Lancet. i:1974;469-473.
4. Reunanen A., Takkunen H., Aromaa A. Prevelance of intermittent claudication and its effect on mortality. Acta Med Scand. 211:1982;249-256.
5. Dormandy J., Mahir M., Ascady G., et al. Fate of the patient with chronic leg ischemia. J Cardiovasc Surg. 30:1989;50-57.
6. Coni N., Tennison B., Troup M. Prevalence of lower extremity arterial disease among elderly people in the community. Br J Gen P. 42:1992;149-152.
7. Dormandy J, Mahia M, Ascady G, et al. Fate of patients with chronic leg ischaemia. J Cardiovasc 1989;30:50-57.
8. Hughson W.G., Mann J.J., Tibbs D.J., Woods H.F., Walton I. Intermittent claudication factors determining outcome . BMJ. 1:1978;1377-1379.
9. Criqui M.H., Langer R.D., Froner A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. NEJM. 326:1992;381-386.
10. Spitzer S., Bach R., Schieffer H. Walk training and drug treatment in patients with peripheral arterial occlusive disease. Int Angiol. 11:1992;204-210.
11. Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
12. Goldhaber S.Z., Manson J.E., Stampfer M.J., et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet. 340:1992;143-145.
13. Giansante C., Calabrese S., Fisicaro M., Fiotti N., Mitri E. Treatment of intermittent claudication with antiplatelet agents. J Int Med Res. 18:1990;400-407.
14. Allegra C., Pollari G., Carioti B., Sardina M. Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with aspirin in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Int J Clin Pharmacol Ther. 32:1994;464-651.
15. Andreozzi G.M., Signorelli S.S., Cacciaguerra G., et al. Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Angiology. 44:1993;307-313.
16. Neri Serneri G.G., Rovelli F., Gensini G.F., Pirelli S., Carnovali M., Fortini A. Effectiveness of low-dose heparin in the prevention of myocardial infarction. Lancet. 4:1987;937-942.
17. Fisher RA, Yates F. Statistical Tables for Biological, Agricultural and Medical Research, 6th ed. Oliver and Boyd, Edinburgh, Tweedale Court, 1970:134.
18. Diggle P., Liang K.Y., Zeger S.L. Analysis of Longitudinal Data. 1994;74-115 Clarendon Press, Oxford.
19. SAS Institute Inc. SAS Technical Report P-229, SAS/STAT Guide for Personal Computers, Version 6.07. Cary, NC: SAS Institute Inc, 1997:287-368.
20. Demol P, Weihrauch TR. What are valid measurements of drug efficacy in patients with intermittent claudication? In: Nimmo W, Tucker G, eds. Clinical Measurement in Drug Evaluation.New York: John Wiley & Sons, 1995:151-171.
21. Porter J.M., Lee B.S., Reich T., et al. Pentoxyfilline efficacy in the treatment of intermittent claudication multicentre controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients . Am Heart J. 104:1982;66-72.
22. Ceriello A., Sardina M., Motz E., Lizzio S., Tuniz D., Bianchini C. Effects of iloprost, either administered for 1 week or for 4 weeks, on systemic haemodynamics, peripheral blood flow and exercise tolerance, in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III. Int J Angiol. 7:1998;28-33.
23. Loosemore T.M., Chalmers T.C., Dormandy J.A. A meta-analysis of randomised placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol. 13:1994;133-142.
24. Donaldson M.C., Matthew E.T., Hadjimichael J., et al. Markers of thrombotic activity in arterial disease. Arch Surg. 122:1987;897-900.
25. Patrono C. Aspirin and human platelets from clinical trials to acetylation of cyclooxygenase and back . Trends Pharmacol Sci. 10:1989;453-458.
26. Sinzinger H., Silberbauer K., Kaliman J., Fitscha P. 20 mg aspirin daily evidence for a clinical future of this extremely low-dose in arterial disease? VASA. 17:1988;10-15.